PainReform Ltd. (NASDAQ:PRFX) Short Interest Update

PainReform Ltd. (NASDAQ:PRFX – Get Free Report) was the target of a significant decrease in short interest in the month of June. As of June 15th, there was short interest totaling 57,440 shares, a decrease of 81.7% from the May 31st total of 313,070 shares. Based on an average daily trading volume, of 4,968,100 shares, the short-interest ratio is presently 0.0 days. Currently, 10.1% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PainReform in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Get PainReform alerts:

View Our Latest Stock Analysis on PRFX

PainReform Stock Down 5.6%

Shares of NASDAQ PRFX traded down $0.09 during mid-day trading on Friday, hitting $1.51. 432,114 shares of the company were exchanged, compared to its average volume of 6,596,596. The stock has a 50 day simple moving average of $1.83 and a 200-day simple moving average of $2.83. PainReform has a 1-year low of $1.28 and a 1-year high of $17.95. The firm has a market cap of $1.31 million, a price-to-earnings ratio of -0.00 and a beta of 0.98.

PainReform (NASDAQ:PRFX – Get Free Report) last announced its quarterly earnings data on Thursday, March 26th. The company reported ($1.01) earnings per share (EPS) for the quarter.

PainReform Company Profile

(Get Free Report)

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.

Recommended Stories

• Five stocks we like better than PainReform
• As Stablecoins Keep Growing, These 2 Stocks Benefit
• Apple Just Handed These 4 Memory Stocks Their Best News of the Year
• Costco’s Secret Growth Engine May Be Running Out of Gas
• Why Alphabet’s Pullback May Be an Opportunity in Disguise

Receive News & Ratings for PainReform Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PainReform and related companies with MarketBeat.com's FREE daily email newsletter.